Wednesday, November 29, 2017


ADMA ADMA Biologics Inc gains 20% Nov 29, 2017

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate is RI-002, a plasma-derived, polyclonal immune globulin intravenous that is in Phase III clinical study for the treatment of primary immune deficiency disease. The company also operatesADMA BioCenters Georgia, Inc, which is a plasma collection center. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive